BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24143237)

  • 1. Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET.
    Ikotun OF; Marquez BV; Huang C; Masuko K; Daiji M; Masuko T; McConathy J; Lapi SE
    PLoS One; 2013; 8(10):e77476. PubMed ID: 24143237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
    Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
    J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET).
    Habermeier A; Graf J; Sandhöfer BF; Boissel JP; Roesch F; Closs EI
    Amino Acids; 2015 Feb; 47(2):335-44. PubMed ID: 25385314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
    Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
    J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
    Kanai Y
    Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A radiopharmaceutical [
    Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
    Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
    J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosynthesis and Preclinical Evaluation of
    Gröner B; Hoffmann C; Endepols H; Urusova EA; Brugger M; Neumaier F; Timmer M; Neumaier B; Zlatopolskiy BD
    Mol Pharm; 2024 Jun; 21(6):2795-2812. PubMed ID: 38747353
    [No Abstract]   [Full Text] [Related]  

  • 10.
    Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
    Molecules; 2020 May; 25(10):. PubMed ID: 32429033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2.
    Aoki M; Watabe T; Nagamori S; Naka S; Ikeda H; Kongpracha P; Horitsugi G; Kanai Y; Shimosegawa E; Kanai Y; Hatazawa J
    Ann Nucl Med; 2019 Jun; 33(6):394-403. PubMed ID: 30820863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (x
    Krys D; Mattingly S; Glubrecht D; Wuest M; Wuest F
    Mol Imaging Biol; 2020 Dec; 22(6):1562-1571. PubMed ID: 32789819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New fluoroethyl phenylalanine analogues as potential LAT1-targeting PET tracers for glioblastoma.
    Verhoeven J; Hulpia F; Kersemans K; Bolcaen J; De Lombaerde S; Goeman J; Descamps B; Hallaert G; Van den Broecke C; Deblaere K; Vanhove C; Van der Eycken J; Van Calenbergh S; Goethals I; De Vos F
    Sci Rep; 2019 Feb; 9(1):2878. PubMed ID: 30814660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Light-Induced Radiosynthesis of
    Klingler S; Fay R; Holland JP
    J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Watabe T; Ikeda H; Nagamori S; Wiriyasermkul P; Tanaka Y; Naka S; Kanai Y; Hagiwara K; Aoki M; Shimosegawa E; Kanai Y; Hatazawa J
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):321-331. PubMed ID: 27550420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
    Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
    J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging.
    Wei L; Tominaga H; Ohgaki R; Wiriyasermkul P; Hagiwara K; Okuda S; Kaira K; Oriuchi N; Nagamori S; Kanai Y
    Cancer Sci; 2016 Mar; 107(3):347-52. PubMed ID: 26749017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
    Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
    Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.